Roth MKM raised the firm’s price target on Chemomab Therapeutics to $9 from $7 and keeps a Buy rating on the shares. The analyst cites results for the company’s Phase II SPRING Trial, where CM-101 met both the primary and secondary endpoints, demonstrating a favorable safety profile over a 15-week treatment period. Patients treated with CM-101 who had moderate to advanced disease showed statistically significant improvements across a variety of disease-related secondary endpoints, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Chemomab’s CM-101 Shows Promise in PSC Trial
- Chemomab Therapeutics announces $10M private placement
- Chemomab Therapeutics Announces $10 Million Private Placement
- Chemomab Therapeutics announces Phase 2 trial results for CM-101
Questions or Comments about the article? Write to editor@tipranks.com